Company Overview and News

 
Duketon Mining extends strike length at Golden Star in Eastern Yilgarn province

2018-04-19 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) has released assay results for the Golden Star prospect in Western Australia, boosting management’s confidence that it is on to a larger gold zone.

 
St Barbara takes 12.3% stake in Duketon Mining

2018-04-05 australianmining.com.au
Australian gold exploration and production company St Barbara has paid $4 million for 14.5 million shares of Duketon Mining at a price of 27.5 cents per share, representing a 12.3 per cent investment in the company.

 
Resolute, St Barbara invest $9m in junior explorers

2018-04-04 businessnews.com.au
Gold miner St Barbara has invested $4 million in local explorer Duketon Mining, while Resolute Mining has announced it will take a $5.1 million stake in a Canadian gold-focused company.

 
Duketon Mining surges after St Barbara Ltd’s $4 million investment in gold-nickel strategy

2018-04-04 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) has surged to a new 12-month high of 30 cents on news of a $4 million investment by mid-tier gold producer St Barbara Ltd (ASX:SBM).

 
Gold miners invest $9m

2018-04-04 businessnews.com.au
Gold miner St Barbara has invested $4 million in local explorer Duketon Mining, while Resolute Mining has announced it will take a $5.1 million stake in a Canadian gold-focused company.

 
Duketon Mining receives strong gold assays from drill program

2017-06-16 proactiveinvestors.com.au
Duketon Mining (ASX:DKM) has received strong gold assays from drilling at the Lancefield North and Golden Star prospects in Western Australia.

 
Duketon Mining shares ride higher on high-grade gold assays

2017-02-01 proactiveinvestors.com.au
Importantly, individual assays are indicating higher grades in parts with a single assay returning 119 g/t gold.

 
Duketon Mining hits high-grade gold at joint venture projects

2016-10-16 proactiveinvestors.com.au
The Petra North project is located immediately adjacent to Regis’ 100% owned Petra project in Western Australia, which has a reported resource of 44,000 ounces gold. The follow up air core drill program at Petra North was designed to test intercepts received in the first air core program last quarter. 46 holes have been completed for 4,506 metres which returned best results of 3 metres at 6.12 g/t gold from 64 metres and 3 metres at 11.

 
Duketon Mining Ltd gets ready to raise

2016-08-10 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare. The halt will remain in place until the opening of trade on Friday 12th August 2016, or earlier if an announcement is made to the market.

 
Duketon identifies gold at Petra North

2016-07-12 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Duketon extends gold anomaly

2016-06-15 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Duketon extends gold anomaly

2016-06-15 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Duketon Mining Ltd shares spike on discovery of large gold anomaly in WA

2016-05-02 proactiveinvestors.com.au
Duketon Mining Ltd (ASX:DKM) seeks to unlock the nickel and gold potential of its Duketon Project in Western Australia’s Duketon Greenstone Belt near major deposits such as Regis Resources’ 3Moz Garden Well deposit.

 

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...